Abivax pares gain after denying AstraZeneca speculation

Abivax pares gain after denying AstraZeneca speculation
Momentum traders are flagging several health care stocks that may be overheated heading into the new quarter. As of Feb. 18, 2026, elevated RSI readings suggest recent gains could be vulnerable to pullbacks despite strong headlines. AstraZeneca has surged roughly 14% over the https://t.co/eVMOTmA1TE
AstraZeneca profit climbs on cancer and heart drug demand
Walmart joins Nasdaq 100 on January 20, replacing AstraZeneca
AstraZeneca hails major breakthroughs with breast-cancer drugs
AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.
290.6BUSD
Type
Common Stock
Aandelenbeurs
PINK
Valuta code
USD
Valutanaam
US Dollar
Naam van het land
USA
Land-ISO
US
IS IN
GB0009895292
CUSIP
-
Sector
Healthcare
Industrie
Drug Manufacturers - General
Einde boekjaar
December
IPO-datum
-
Bijgewerkt op
-
P / E verhouding
31.09
PEG-ratio
1.67
Boekwaarde
29.59
Dividendaandeel
3.13
Dividendrendement
1.70%
Winstaandeel
6.03
Richtprijs Wall Street
104.00
EPS-schatting huidig jaar
4.56
EPS-schatting volgend jaar
5.06
EPS-schatting huidig kwartaal
0
EPS-schatting volgend kwartaal
0
Meest recente kwartaal
-
Inkomsten TTM
58,126,999,552
Brutowinst TTM
48,395,001,856
EBITDA
20,416,000,000
Winstmarge
16.17%
Rendement op activa TTM
9.06%
Rendement op eigen vermogen TTM
21.67%
Opbrengst per aandeel TTM
37.501
Qtly omzetgroei op jaarbasis
12.00%
Verdunde Eps TTM
6.03
Qtly winstgroei op jaarbasis
78.00%
Achterlopende PE
31.09
Voorwaarts PE
19
Prijs Verkoop TTM
4.9994
Prijsboek MRQ
6.1782
Bedrijfswaarde-inkomsten
5
Bedrijfswaarde EBITDA
17
400.00
3.27%356.82
2.03%50.08
1.48%155.25
0.55%242.30
0.44%212.23
0.23%955.46
0.20%146.63
-5.33%393.19
-1.70%122.68
-0.41%